

Wayne K. Anderson, Ph.D. - Biostatement

Dr. Wayne K. Anderson is Dean of the School of Pharmacy and Pharmaceutical Sciences, Professor of Pharmaceutical Sciences, Professor of Chemistry and Professor of Medicinal Chemistry at the State University of New York at Buffalo. His career emphasis has been in support of SUNY's mission by servicing the greater good through research, scholarship and leadership...

Dean Anderson is an accomplished teacher, scientist and community advocate. As a scientist, he is author of more than 100 primary research publications. His personal research programs, funded continuously for 25 years, have produced scientific contributions with profound impact in the areas of cancer and AIDS. His research productivity has led to the invention of numerous drugs which have progressed to preclinical and clinical human trial. Dean Anderson is also responsible for the development of eight patents.

As mentor and teacher, Dean Anderson has trained 30 PhD students, 9 MS students, 30 postdoctoral scholars, provided research experiences for more than 50 undergraduate and honors students, and had guided countless pharmacy students to successful career paths.

In 1994, Dean Anderson stepped forward from the faculty ranks to become 10th dean of the UB School of Pharmacy and Pharmaceutical Sciences, the only Pharmacy Program in the SUNY system.

As Dean, one of his greatest career impacts has been through his leadership in advancing health care educational opportunities for underserved populations in Western New York and New York State. He has worked with the *Area Health Education Centers (AHEC)* since 1998. He has served also as a member of the *Erie-Niagara Area Health AHEC Coordinating Committee* and Board of Directors, where he was Chairman from 2004-2006. Additional service in this arena includes membership on the NYS AHEC Advisory Committee since 1998, and membership in the *Partners for a Healthy Community* since 2002. Dean Anderson has also carried this mission forward within the School of Pharmacy and Pharmaceutical Sciences by increasing enrollment of underrepresented populations in all educational programs.

Dean Anderson's enduring achievements in intellectual life as well as outstanding service not only impact our internal campus community, but also our external regional and community partners, particularly in support and outreach to under-represented populations in the health professions as well under-served health care populations. His teaching and mentoring has not only touched the many students, fellows and post-docs with whom he has had direct contact, but also has had positive impact upon the many more who have benefited from his emphasis on continuing elevation and excellence of the School's academic programs.

NOTABLE AREAS OF ACCOMPLISHMENT AS DEAN:

Education

- worked collaboratively with the other three (private) Pharmacy Schools in New York and with constituent professional pharmacy organizations to secure approval

- from the NY State Department of Education for the Pharm.D. as the first professional degree in NY State
- established the new entry-level Doctor of Pharmacy (Pharm.D.) program at UB and developed a transitional program for the (then) current B.S. in Pharmacy students
 - established new American Society of Health-Systems Pharmacists (ASHP)-accredited ambulatory and institutional post-Pharm.D. residency programs
 - developed cooperative post PharmD fellowship programs with the pharmaceutical industry
 - established combined B.S./M.S. programs in the pharmaceutical sciences as well as new MS foci (*e.g.*, pharmacometrics)
 - established programs to assess student learning outcomes as part of a continuing curriculum assessment and development program
 - worked collaboratively with the Vice President for Health Sciences and the health science deans toward greater collaborations in inter-professional education in an Academic Health Center model

Research

- increased total NIH funding from \$1,227,601 in 2000 (\$102,300 per FTE for 12 FTE faculty) to 3,422,188 in 2005 (\$228,544 per FTE for 15 FTE faculty) and rose from 19th in total NIH funding per PhD faculty FTE to 9th. (*American Association of Colleges of Pharmacy* data). The school ranks second in per PhD FTE funding on individual grants.
 - This growth required strategic investment in faculty and infrastructure
- developed a pharmacogenomics program in collaboration with the functional genomics programs in the School of Medicine & Biomedical Sciences and Roswell Park Cancer Institute
- established a Pharmacotherapy Research Center (PRC) with a core analytical laboratory, a core in-patient clinical research unit and a range of practice focus groups (*e.g.*, in critical care, ambulatory care, oncology, infectious disease, pediatrics, geriatrics, *etc.*)
- established a central major instrumentation center in the School of Pharmacy and Pharmaceutical Sciences to bring new technologies to support the school's faculty, to promote translational research and stimulate development of CDDET and the PRC
- established the Pfizer Center of Excellence in Pharmacokinetics & Pharmacodynamics

Development and Alumni Affairs

- created a School of Pharmacy and Pharmaceutical Sciences Development Office that was the "lead unit" in UB's \$250 million capital campaign (and exceeded the \$18 million School of Pharmacy and Pharmaceutical Sciences goal).
- established School of Pharmacy and Pharmaceutical Sciences Dean's Council
- successfully completed a \$2 million Kresge Foundation Challenge Grant – the first and only successful UB Kresge Challenge Grant.

Professional Relations and Professional Practice

- established web-based drug information networks in HIV/AIDS, asthma and diabetes - the *ePharmacotherapy Network*[®]
- established advanced practice sites for pharmaceutical care/patient management in ambulatory, acute and long-term care environments
- worked with professional associations, pharmacy practitioners and pharmacy students to inform State and Federal elected representatives on issues relating to pharmacy practice and to lead efforts to change laws and regulations concerning pharmacy practice

Student Recruitment, Enrollment and Retention

- modified admission criteria to allow students to document “special circumstances”
- increased the diversity of the entering PharmD class from 1-2% to 12-15% through more aggressive recruitment practices
- increased (>4-fold) the School of Pharmacy and Pharmaceutical Sciences endowed support for student scholarships
- established articulation agreements with regional four-year colleges for School of Pharmacy and Pharmaceutical Sciences admissions program

DEAN COMMITTEES AND ADMINISTRATIVE ACTIVITIES

1995-1999	Member, University at Buffalo Council on Research and Sponsored Programs (“ <i>CRSP</i> ”)
1995-1996	Member, Search Committee for Technology Transfer Director for SUNY Buffalo
1995-date	Member, Joint Hospital-University Committee
1995-1998	Member, University at Buffalo’s Structural Biology Steering Committee
1995-1998	Member, University at Buffalo Health Professional Instructional Technology Steering Committee
1996	Member, Search Committee for the Director of Administrative Computing at the University at Buffalo
1996-1999	Member, University at Buffalo Equal Opportunity/Affirmative Action Committee
1997-1998	Secretary, New York State Pharmacy Council
1997-date	Member, University at Buffalo Clinical Research Steering Committee
1998-date	Member, New York State Area Health Education Centers (AHEC) Advisory Committee
1995-date	Member, New York State Pharmacy Council
1998-2000	Chairman, New York State Pharmacy Council

2002-2004	Member, Erie-Niagara AHEC Coordinating Committee
2002-date	Member, “Partners for a Healthy Community” Board of Directors
2003	Member, Erie-Niagara AHEC Executive Director Search Committee
2004-2006	Chairman, “Erie-Niagara AHEC” Board of Directors
2004-2005	Member, University at Buffalo’s Vice President for Health Sciences Search Committee
2005-2006	Chairman, University at Buffalo Development Committee (the “Anderson Committee”)
2005-date	Member, University at Buffalo Space Management and Facilities Planning Committee
2005-date	Member, University at Buffalo Strategic Strength Steering Committees
2006-date	Member, Erie-Niagara AHEC Advisory Board

National and International Committees

- Member, 2006, *American Council on Pharmaceutical Education* (ACPE) accreditation team for the East Tennessee State University College of Pharmacy
- Member, 2004-2005, *American Association of Colleges of Pharmacy* (AACP) Task Force on Professional Practice Plans
- Member, 2004, National Cancer Institute H. Lee Moffitt Cancer Center and Research Institute Program Project Review Team
- Member, 2003, National Cancer Institute Stanford University Program Project Review Group
- Member, 2003, *American Council on Pharmaceutical Education* (ACPE) accreditation team for the University of New Mexico School of Pharmacy
- *Ad hoc* member, 2003, NIH Grant Review Study Section (Program Projects).
- Member, 2002-2003, American Association of Colleges of Pharmacy (AACP) Council of Deans Nomination Committee
- Member, 2002-date, *United States Pharmacopoeia* Conventions Member
- Graduate program evaluator, 2003, University of Colorado School of Pharmacy
- Member, 2001-2002, *American Council on Pharmaceutical Education* (ACPE) accreditation team for the University of Colorado School of Pharmacy
- Member, 2001-2002, *American Association of Colleges of Pharmacy* (AACP) Graduate Affairs Committee
- Member, 1997-1998, *American Association of Colleges of Pharmacy* (AACP) Graduate Affairs Committee

- Chairman, 1996-1997, *American Association of Colleges of Pharmacy* (AACP) Research and Graduate Affairs Committee
- Member, 1995-2000, National Research Council Chemical Sciences Review Panel, National Academy of Sciences.

RESEARCH SUPPORT as Principal Investigator (\$4,023,037.07 *Direct Costs Only*)

1. "A Systematic Search for Naturally-Occurring Tumor-Inhibitory Substances" (50-8600E) awarded by the SUNY Buffalo National Science Foundation Institutional Grant Committee:
06/18/69 - 08/31/70 \$560.00
2. "Studies on the Metabolism of Tumor-Inhibitory Bis(benzylisoquinoline Alkaloids)" awarded by the SUNY Buffalo, Institutional Funds Committee:
12/03/73 - 11/30/74 \$980.00
3. "The Synthesis of Polyfunctional Tumor Inhibitors" (RO1-CA-11880) awarded by the NCI, NIH, DHEW:
04/01/71 - 03/31/72 \$21,934.00
04/01/72 - 03/31/73 \$17,083.00
04/01/73 - 03/31/74 \$3,827.00
05/01/74 - 04/30/75 \$23,534.00
05/01/75 - 04/30/76 \$22,243.00
05/01/76 - 04/30/77 \$22,655.00
4. "Research Training and Development of Anticancer Drugs" (IT2-CA-09166) awarded by the NCI, NIH, DHEW:
07/01/75 - 06/30/76 \$63,073.00
07/01/76 - 06/30/77 \$107,727.00
07/01/77 - 06/30/78 \$116,018.00
07/01/78 - 06/30/80 \$132,006.00
5. Miscellaneous Small Contracts from the NCI, NIH, DHEW:
11/11/77 263-78-M2106 \$2,000.00
03/28/78 263-MD-805351 \$1,000.00
12/12/78 263-M9-905166 \$3,010.00
03/02/79 263-MD-912367 \$1,000.00
03/01/80 263-ME-013684 \$4,000.00
01/09/81 263-MD-109969 \$9,900.00
04/08/81 263-MD-121372 \$9,800.00
03/06/85 263-MD-513556 \$9,600.00
03/26/85 263-MD-511489 \$4,400.00
11/05/85 263-MD-603429 \$5,800.00
04/09/86 263-MD-616777 \$2,700.00

6. "Vinylogous Carbinolamine Tumor Inhibitors" (RO1-CA-22935) awarded by the NCI, NIH, DHEW:
- | | |
|---------------------|-------------|
| 08/01/77 - 07/31/78 | \$31,493.00 |
| 08/01/78 - 07/31/79 | \$30,073.00 |
| 08/01/79 - 07/31/80 | \$32,143.00 |
| 08/01/80 - 07/31/81 | \$40,926.00 |
| 08/01/81 - 07/31/82 | \$39,822.00 |
| 08/01/82 - 07/31/83 | \$40,478.00 |
| 08/01/83 - 07/31/84 | \$54,670.00 |
| 08/01/84 - 07/31/85 | \$57,892.00 |
| 08/01/85 - 07/31/86 | \$61,307.00 |
7. Japan Atherosclerosis Research Foundation Postdoctoral Fellowship on behalf of Dr. Y. Eguchi:
- | | |
|---------------------|------------|
| 04/01/81 - 08/31/84 | \$7,000.00 |
|---------------------|------------|
8. "The Synthesis of Congeners and Prodrugs" (NO1-CM-27570) awarded by the NCI, NIH, DHEW:
- | | |
|---------------------|--------------|
| 09/30/82 - 03/31/84 | \$214,513.00 |
| 04/01/84 - 03/31/85 | \$138,144.00 |
| 04/01/85 - 03/31/86 | \$128,964.00 |
9. Royalty Income Distribution Account. Research Foundation of SUNY:
- | | |
|----------|------------|
| 07/01/83 | \$1,440.00 |
| 07/01/85 | \$1,891.27 |
| 12/01/87 | \$1,594.80 |
| 12/01/88 | \$1,772.00 |
10. SUNY Buffalo Postdoctoral Fellowship Award for Dr. Lei Chang:
- | | |
|---------------------|-------------|
| 02/01/85 - 01/31/87 | \$17,500.00 |
|---------------------|-------------|
11. "The Synthesis of Congeners and Prodrugs" (NO1-CM-67698) awarded by the NCI, NIH, DHHS:
- | | |
|---------------------|--------------|
| 05/13/86 - 05/12/87 | \$112,692.00 |
| 05/13/87 - 05/12/88 | \$196,901.00 |
| 05/13/88 - 05/12/89 | \$120,449.00 |
| 05/13/89 - 05/12/90 | \$120,880.00 |
| 05/13/90 - 05/12/91 | \$88,335.00 |
12. "Novel Pyridone Antineoplastic Agents" (RO1-CA-41540) awarded by the NCI, NCI, DHHS:
- | | |
|---------------------|-------------|
| 04/01/86 - 03/31/87 | \$55,181.00 |
| 04/01/87 - 03/31/88 | \$57,245.00 |
| 04/01/88 - 03/31/90 | \$62,603.00 |

13. Ministry of Agriculture, Fishery and Fishery Husbandry of P.R. China, Fellowship for Tan Pingzhong:
01/01/88 - 12/31/89 \$7,000.00
14. Mitsubishi Chemical Industries Limited, general support for Dr. Wayne K. Anderson:
"Anticancer Compounds."
04/08/88 - 04/09/89 \$40,728.00
11/30/90 - 09/30/93 \$54,259.00
15. "Synthesis of Congeners and Prodrugs of Anti-AIDS Compounds" (NO1-CM-87216) awarded by the NIH, DHHS:
05/31/88 - 04/30/89 \$168,398.00
05/31/89 - 04/30/90 \$176,581.00
05/31/90 - 04/30/91 \$185,946.00
16. "Synthesis of Isopropyl Pyrrolizine Biscarbamate", Unimed Corporation:
06/88 \$5,000.00
17. "Design, Synthesis and Study of IMPD Inhibitors" (RO1-CA54507) awarded by the NIH, DHHS.
04/01/91 - 03/31/92 \$112,341.00
04/01/92 - 03/31/93 \$114,199.00
04/01/93 - 03/31/95 \$118,562.00
18. "Small Instrumentation Grant" (S15-CA55948) awarded by the NIH, DHHS.
09/01/91 - 08/31/92 \$13,433.00
19. "Synthesis of Congeners and Prodrugs" (NO1-CM-17569) awarded by the Drug Development Program, Division of Cancer Treatment, NCI, NIH, DHHS.
10/01/91 - 9/31/92 \$130,734.00
10/01/92 - 9/31/93 \$137,362.00
10/01/93 - 9/31/94 \$144,805.00
10/01/94 - 9/31/95 \$152,426.00
10/01/95 - 9/31/96 \$160,504.00